A study (2004) reported that immunoreactive (ir) ILK is an ovarian tumor antigen and that the expression of irILK in the serum of patients with grade 1,2,3 ovarian cancers is 6–9 times greater than the serum of normal patients with benign tumors (25). This evidence concerns the gene ILK and ovarian neoplasm.